drugset / Trial / NCT07172724
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Phase 1
Not yet recruiting
48 enrolled
Federal University of Minas Gerais
CT Vacinas - Centro de Tecnologia em Vacinas/Universidade Federal de Minas Gerais · collabFinanciadora de Estudos e Projetos · collabFundação de Amparo à Pesquisa do Estado de São Paulo · collabINCTV National Institute of Vaccine Science and Technology · collabThe Ministry of Science, Technology and Innovation, Brazil · collabUniversity of Sao Paulo · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
Timeline
- Start
- 2025-09
- Primary completion
- 2026-03
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vivaxin | Vaccine | 25 ug | Intramuscular |
| Subject | Vivaxin | Vaccine | 50 ug | Intramuscular |
| Subject | Vivaxin | Vaccine | 100 ug | Intramuscular |